Lydon Nicholas 4
4 · Blueprint Medicines Corp · Filed Jul 6, 2020
Insider Transaction Report
Form 4
Lydon Nicholas
Director
Transactions
- Sale
Common Stock
2020-07-01$80.21/sh−1,300$104,273→ 76,572 total - Sale
Common Stock
2020-07-02$80.13/sh−2,825$226,367→ 73,747 total
Footnotes (3)
- [F1]Effected pursuant to a trading plan adopted on February 27, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.03 to $80.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.50 per share.